Javascript must be enabled to continue!
Colon cancer molecular subtypes identified by expression profiling and associatedto stroma, mucinous type and different clinical behavior
View through CrossRef
AbstractBackgroundColon cancer patients with the same stage show diverse clinical behavior dueto tumor heterogeneity. We aimed to discover distinct classes of tumorsbased on microarray expression patterns, to analyze whether the molecularclassification correlated with the histopathological stages or otherclinical parameters and to study differences in the survival.MethodsHierarchical clustering was performed for class discovery in 88 colon tumors(stages I to IV). Pathways analysis and correlations between clinicalparameters and our classification were analyzed. Tumor subtypes werevalidated using an external set of 78 patients. A 167 gene signatureassociated to the main subtype was generated using the 3-Nearest-Neighbormethod. Coincidences with other prognostic predictors were assesed.ResultsHierarchical clustering identified four robust tumor subtypes withbiologically and clinically distinct behavior. Stromal components(p < 0.001), nuclear β-catenin (p = 0.021),mucinous histology (p = 0.001), microsatellite-instability(p = 0.039) and BRAF mutations (p < 0.001) wereassociated to this classification but it was independent of Dukes stages(p = 0.646). Molecular subtypes were established from stage I.High-stroma-subtype showed increased levels of genes and altered pathwaysdistinctive of tumour-associated-stroma and components of the extracellularmatrix in contrast to Low-stroma-subtype. Mucinous-subtype was reflected bythe increased expression of trefoil factors and mucins as well as by ahigher proportion of MSI andBRAFmutations. Tumor subtypes werevalidated using an external set of 78 patients. A 167 gene signatureassociated to the Low-stroma-subtype distinguished low risk patients fromhigh risk patients in the external cohort (Dukes B andC:HR = 8.56(2.53-29.01); Dukes B,C andD:HR = 1.87(1.07-3.25)). Eight different reported survival genesignatures segregated our tumors into two groups the Low-stroma-subtype andthe other tumor subtypes.ConclusionsWe have identified novel molecular subtypes in colon cancer with distinctbiological and clinical behavior that are established from the initiation ofthe tumor. Tumor microenvironment is important for the classification andfor the malignant power of the tumor. Differential gene sets and biologicalpathways characterize each tumor subtype reflecting underlying mechanisms ofcarcinogenesis that may be used for the selection of targeted therapeuticprocedures. This classification may contribute to an improvement in themanagement of the patients with CRC and to a more comprehensiveprognosis.
Springer Science and Business Media LLC
Title: Colon cancer molecular subtypes identified by expression profiling and associatedto stroma, mucinous type and different clinical behavior
Description:
AbstractBackgroundColon cancer patients with the same stage show diverse clinical behavior dueto tumor heterogeneity.
We aimed to discover distinct classes of tumorsbased on microarray expression patterns, to analyze whether the molecularclassification correlated with the histopathological stages or otherclinical parameters and to study differences in the survival.
MethodsHierarchical clustering was performed for class discovery in 88 colon tumors(stages I to IV).
Pathways analysis and correlations between clinicalparameters and our classification were analyzed.
Tumor subtypes werevalidated using an external set of 78 patients.
A 167 gene signatureassociated to the main subtype was generated using the 3-Nearest-Neighbormethod.
Coincidences with other prognostic predictors were assesed.
ResultsHierarchical clustering identified four robust tumor subtypes withbiologically and clinically distinct behavior.
Stromal components(p < 0.
001), nuclear β-catenin (p = 0.
021),mucinous histology (p = 0.
001), microsatellite-instability(p = 0.
039) and BRAF mutations (p < 0.
001) wereassociated to this classification but it was independent of Dukes stages(p = 0.
646).
Molecular subtypes were established from stage I.
High-stroma-subtype showed increased levels of genes and altered pathwaysdistinctive of tumour-associated-stroma and components of the extracellularmatrix in contrast to Low-stroma-subtype.
Mucinous-subtype was reflected bythe increased expression of trefoil factors and mucins as well as by ahigher proportion of MSI andBRAFmutations.
Tumor subtypes werevalidated using an external set of 78 patients.
A 167 gene signatureassociated to the Low-stroma-subtype distinguished low risk patients fromhigh risk patients in the external cohort (Dukes B andC:HR = 8.
56(2.
53-29.
01); Dukes B,C andD:HR = 1.
87(1.
07-3.
25)).
Eight different reported survival genesignatures segregated our tumors into two groups the Low-stroma-subtype andthe other tumor subtypes.
ConclusionsWe have identified novel molecular subtypes in colon cancer with distinctbiological and clinical behavior that are established from the initiation ofthe tumor.
Tumor microenvironment is important for the classification andfor the malignant power of the tumor.
Differential gene sets and biologicalpathways characterize each tumor subtype reflecting underlying mechanisms ofcarcinogenesis that may be used for the selection of targeted therapeuticprocedures.
This classification may contribute to an improvement in themanagement of the patients with CRC and to a more comprehensiveprognosis.
Related Results
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract
Epithelial ovarian cancer (EOC) accounts for 5% of all cancer deaths and is the fifth leading cause of cancer death in women in the United States. While the...
Mortality and morbidity outcomes in patients with inflammatory bowel disease with colon cancer: A nationwide analysis.
Mortality and morbidity outcomes in patients with inflammatory bowel disease with colon cancer: A nationwide analysis.
e15669
Background:
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic condition chara...
Abstract B8: Molecular subtyping of epithelial ovarian cancer reveals connections to intrinsic breast cancer subtypes
Abstract B8: Molecular subtyping of epithelial ovarian cancer reveals connections to intrinsic breast cancer subtypes
Abstract
Aim: Epithelial ovarian cancer is one of the most lethal female cancers. It is a heterogeneous group of neoplasms and the different histologic subtypes are ...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Podoplanin-mediated platelet activation promotes proliferation and invasion of colon cancer cells
Podoplanin-mediated platelet activation promotes proliferation and invasion of colon cancer cells
Abstract
Background: Recent studies have shown that podoplanin is highly expressed in many tumors, suggesting that podoplanin may be related to the invasion and metastasis ...
Abstract 1690: LSD1 and CoREST2 demethylate STAT3 to promote enteroendocrine cell differentiation in mucinous colorectal cancer
Abstract 1690: LSD1 and CoREST2 demethylate STAT3 to promote enteroendocrine cell differentiation in mucinous colorectal cancer
Abstract
Across different cancer types, tumor heterogeneity has been shown to drive tumor progression, metastasis, and therapeutic resistance. Adenocarcinoma to neur...
Abstract 5594: Inmune gene expression by nCounter in mucinous adenocarcinoma lung cancer
Abstract 5594: Inmune gene expression by nCounter in mucinous adenocarcinoma lung cancer
Abstract
Introduction: Although immune checkpoint inhibitors have become a standard of care for multiple cancer types; currently used biomarkers, such as PD-L1 expre...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

